André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s business model, and ensuring that those affected with hepatitis C are able to receive treatment in Switzerland.
A lot has been written about Gilead´s ground-breaking hepatitis C treatment Sovaldi over the past year. How has this product been received in the Swiss market?
In Switzerland there are three times more people infected with HCV than with HIV and people are still unaware of HCV and the consequences of the infection
